3/27
08:02 am
bioa
BioAge Labs (BIOA) is now covered by Needham & Company LLC. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
BioAge Labs (BIOA) is now covered by Needham & Company LLC. They set a "buy" rating and a $50.00 price target on the stock.
3/27
05:20 am
bioa
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Low
Report
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
3/27
05:12 am
bioa
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Low
Report
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
3/24
09:00 am
bioa
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
High
Report
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
3/23
03:50 am
bioa
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
Medium
Report
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
3/10
11:02 am
bioa
BioAge Labs (BIOA) had its price target raised by Citigroup Inc. from $15.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
BioAge Labs (BIOA) had its price target raised by Citigroup Inc. from $15.00 to $52.00. They now have a "buy" rating on the stock.
2/26
10:12 pm
bioa
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
Low
Report
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
2/25
08:00 am
bioa
BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.
Low
Report
BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.
2/19
05:11 pm
bioa
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/19
04:30 pm
bioa
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/11
02:41 am
bioa
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
2/11
02:39 am
bioa
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
2/6
06:23 am
bioa
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Medium
Report
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
2/6
06:17 am
bioa
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Medium
Report
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
2/4
10:15 am
bioa
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
Low
Report
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
2/3
03:37 am
bioa
1/29
06:16 am
bioa
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/27
07:01 am
bioa
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/26
04:13 pm
bioa
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Medium
Report
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
1/26
03:07 am
bioa
Medium
Report
1/21
10:30 pm
bioa
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
Medium
Report
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
1/20
04:18 pm
bioa
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
Low
Report
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
1/20
04:01 pm
bioa
BioAge Announces Proposed Public Offering
Low
Report
BioAge Announces Proposed Public Offering
1/20
09:00 am
bioa
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Medium
Report
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026